Nuclear Medicine Division, Indian Institute of Chemical Biology (CSIR), 4, Raja S. C. Mullick Road, Jadavpur, Kolkata-700032, India.
Metallomics. 2011 Oct;3(10):1041-8. doi: 10.1039/c1mt00068c. Epub 2011 Aug 11.
The aim of this study was to radiolabel ciprofloxacin (Cip) and nitrofuryl thiosemicarbazone (NFT) with the fac-(99m)Tc(CO)(3)(H(2)O)(3) core and to evaluate the ability of the radiopharmaceuticals as tracers in detecting sites of infection. Cip and NFT were radiolabeled with the fac-(99m)Tc(CO)(3)(H(2)O)(3) core and characterized by RHPLC. The stabilities of the preparations were evaluated in saline and rat serum. In vitro binding studies of the radiopharmaceuticals with S. aureus were performed. Biodistribution studies were conducted at different time points after injecting (i.v.) the radiopharmaceuticals in rats (intramuscularly infected with S. aureus) as well as in rats with sterile inflammation. To assess the infection targeting capacity of (99m)Tc-tricarbonyl ciprofloxacin and nitrofuryl thiosemicarbazone, (99m)Tc(v)O-Cip and (99m)Tc(v)O-NFT were used as control. Scintigraphic imaging studies of tricarbonyl compounds and (99m)Tc(v)O-Cip were performed at 4 h after injection. The radiochemical purities of (99m)Tc(CO)(3)-Cip and (99m)Tc(CO)(3)-NFT were between 97-98% as determined by thin layer chromatography (TLRC) and RHPLC; no further purification is necessary before injection. The radiopharmaceuticals exhibited substantial stability when incubated in isotonic saline and serum up to 24 h. Biodistribution studies showed maximum uptake in the infected rat thigh muscle at 4 h post injection and washing out at slower rate from the infected site than the oxo technetium chelate. The mean ratios of uptake in infected/non-infected thighs were 3.87:1, 3.41:1 and 3.17:1 for (99m)Tc(CO)(3)-Cip, (99m)Tc(CO)(3)-NFT and (99m)Tc(v)O-Cip respectively. During scintigraphic studies, infection sites appeared quite distinctly with (99m)Tc(CO)(3)-Cip and (99m)Tc(CO)(3)-NFT, comparable to the behaviour with (99m)Tc(v)O-Cip. These results encouraged us for further development of infection imaging radiopharmaceuticals based on the (99m)Tc-tricarbonyl core.
本研究的目的是用 fac-(99m)Tc(CO)(3)(H(2)O)(3) 核标记环丙沙星(Cip)和硝基呋喃硫代缩氨基脲(NFT),并评估放射性药物作为检测感染部位示踪剂的能力。用 fac-(99m)Tc(CO)(3)(H(2)O)(3) 核标记 Cip 和 NFT,并通过 RHPLC 进行特征分析。评估了制剂在盐水中和大鼠血清中的稳定性。进行了放射性药物与金黄色葡萄球菌体外结合研究。在金黄色葡萄球菌肌肉感染大鼠静脉注射(i.v.)放射性药物后不同时间点进行了放射性药物的生物分布研究,以及在无菌炎症大鼠中进行了研究。为了评估 (99m)Tc 三羰基环丙沙星和硝基呋喃硫代缩氨基脲的感染靶向能力,将 (99m)Tc(v)O-Cip 和 (99m)Tc(v)O-NFT 用作对照。在注射后 4 小时进行了三羰基化合物和 (99m)Tc(v)O-Cip 的闪烁成像研究。通过薄层层析法(TLRC)和 RHPLC 测定,(99m)Tc(CO)(3)-Cip 和 (99m)Tc(CO)(3)-NFT 的放射化学纯度均在 97-98%之间;在注射前无需进一步纯化。放射性药物在等渗盐水和血清中孵育至 24 小时时表现出相当大的稳定性。生物分布研究表明,在感染后 4 小时,放射性药物在注射后最大吸收,从感染部位洗脱速度较慢,低于氧代锝螯合物。(99m)Tc(CO)(3)-Cip、(99m)Tc(CO)(3)-NFT 和 (99m)Tc(v)O-Cip 的感染/非感染大腿摄取比均值分别为 3.87:1、3.41:1 和 3.17:1。在闪烁成像研究中,感染部位用 (99m)Tc(CO)(3)-Cip 和 (99m)Tc(CO)(3)-NFT 清晰显示,与 (99m)Tc(v)O-Cip 的行为相当。这些结果鼓励我们进一步开发基于 (99m)Tc 三羰基核的感染成像放射性药物。